跳至主要内容
临床试验/ACTRN12617000561381
ACTRN12617000561381招募中未知

Gastrointestinal eradication of multi-resistant gram negative bacteria by faecal microbiota transplantation (FMT)

The Queen Elizabeth Hospital0 个研究点目标入组 22 人开始时间: 2017年4月21日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
入组人数
22

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 85 Years(—)
性别
All

入选标准

  • 1. Patients with refractory or recurrent infection–defined as at least 3 episodes of infection requiring at least 3 episodes of antibiotic therapy in preceding 24 months.
  • 2. These infections were caused by a Gram negative bacterium which has acquired clinically important antibiotic resistance. This is defined as reported resistance to one or more of the following antibiotics: meropenem, ceftriaxone, cefepime, ceftazidime, cefalexin, amoxicillin-clavulanate, piperacillin-tazobactam, ciprofloxacin, gentamicin or trimethoprim.

排除标准

  • 1. Active gastrointestinal infection
  • Ie bacterial or viral infection causing symptoms of diarrhoea
  • (colonisation with MRGNB is not considered to be an infection)
  • 2. Pregnancy
  • 3. Current use of antibiotics*
  • 4. Cognitive impairment
  • 5. Perianal inflammation
  • 6. Life expectancy < 1 year
  • 7. Neutropaenia <0.5 X109/L
  • 8. Severe IgE mediated food allergy : urticaria or anaphylaxis
  • 9. At risk of peritonitis: including patients with ascities or peritoneal dialysis
  • *The use of trimethoprim-sulfamethoxazole is allowed when used for prophylaxis against Pneumocystis infection in immunosuppressed individuals.

研究者

相似试验

Gastrointestinal eradication of multi-resistant gram... | 临床试验